From the IMPROVE-IT investigators:
When added to statin therapy, ezetimibe resulted in incremental lowering of LDL cholesterol levels and improved cardiovascular outcomes. Moreover, lowering LDL cholesterol to levels below previous targets provided additional benefit.
The trial involved patients who had had acute coronary syndrome.
With recognition of the powerful pleiotropic effects of statins and the promulgation of the new statin guidelines we have all but forgotten the importance of LDL reduction itself. This was known decades ago based on non statin trials. Nevertheless some have recently made the unwarranted claim that LDL reduction doesn't matter.